.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Oral presentation
14

ADAM10 is upregulated in human heart failure and its pharmacological as well genetic inhibition abolishes CX3CL1-dependent leucocyte infiltration and improves survival and cardiac function after infarction

Appointment

Date: 07/03/2023

Time: 10:15 – 10:30

Talk time: 10 Min.

Discussion time: 5 Min.

Location / Stream:

Session

Cardiac pharmacology and treatment

Topics

Cardiac pharmacology
Disease models, drug development

Authors

Erik Klapproth (Dresden / DE), P. Klose (Dresden / DE), J. Wiedemann (Dresden / DE), A. Witt (Dresden / DE), Stephan Künzel (Dresden / DE), Stefan Weber (Dresden / DE), K. Guan (Dresden / DE), I. Kopaliani (Dresden / DE), P. Mirtschink (Dresden / DE), P. Saftig (Kiel / DE), Kristina Lorenz (Dortmund / DE; Würzburg / DE), Ali El-Armouche (Dresden / DE)